Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Pharming  /  Valeant draadje

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,850 15 mei 2024 17:36
  • -0,018 (-2,07%) Dagrange 0,850 - 0,872
  • 6.708.908 Gem. (3M) 6,6M

Valeant draadje

353 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 18 »» | Laatste | Omlaag ↓
  1. [verwijderd] 9 augustus 2016 13:14
    Valeant Pharmaceuticals International Inc.: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results

    Tickers: VRX

    2016 Full Year Guidance Reconfirmed
    LAVAL, Quebec, Aug. 9, 2016 /PRNewswire/ --
    • Total Revenues of $2.4 billion, a decrease of 11% versus the second quarter of 2015
    • GAAP EPS ($0.88) and Adjusted EPS (non-GAAP) $1.40
    • Cash Flow from Operations of $448 million, an increase of 9% versus the second quarter of 2015

    Top Company Interviews

    Microsoft Corporation

    Intel Corporation

    Pfizer, Inc.

    General Electric Company

    International Business Machines Corporation

    Wal-Mart Stores, Inc.
    Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ('Valeant' or the 'Company') today announced second quarter 2016 financial results.
    'We continue to make progress towards stabilizing the organization,' said Joseph C. Papa, chairman and chief executive officer. 'We are also announcing a new strategic direction for Valeant today, which, at its heart has a mission to improve patients' lives, and will involve reorganizing our company and reporting segments. I am continuously encouraged by the commitment of our employees who work hard daily, rebuilding our relationships with prescribers, patients and payors, and regaining the trust of our debt holders and shareholders. Although it will take time to implement and execute our turnaround plan, I am confident that we will show progress in the coming quarters.'
    Total Revenues
    Total revenues decreased 11% to $2.42 billion in the second quarter of 2016 as compared to $2.73 billion in the second quarter of 2015, driven primarily by a decline in product sales revenues from our existing business, as well as negative foreign currency exchange impact, partially offset by incremental product sales revenues from acquisitions completed in 2015.
    In the Developed Markets segment, revenues declined 14%, driven mainly by a decline in product sales revenue from our existing business, primarily as a result of lower average realized prices which were in turn impacted by higher managed care rebates, lower price appreciation credits, our fulfillment agreement with Walgreens, and higher group purchasing organization (GPO) rebates. These factors were partially offset by an increase in contribution from acquisitions completed in 2015, primarily from Salix Pharmaceuticals, Ltd. and certain assets of Dendreon Corporation.
    In the Emerging Markets segment, revenues were flat as compared to the second quarter of 2015, primarily due to a small decline in the existing business and negative foreign currency exchange impact, which were partially offset by incremental product sales revenue from acquisitions completed in 2015.
    Operating Expenses
    Cost of goods sold were $647 million in the second quarter of 2016 as compared to $670 million in the second quarter of 2015, a decrease of 3% primarily due to a decline in sales volumes, partially offset by increased sales from acquisitions completed in 2015, primarily of Salix and Amoun Pharmaceutical Company S.A.E.
    Selling, general and administrative expenses ('SG&A') were $672 million in the second quarter of 2016, as compared to $686 million in the second quarter of 2015. As a percentage of revenue, SG&A was 28% in the second quarter of 2016, as compared to 25% in the second quarter of 2015.
    Research and development ('R&D') expenses were $124 million in the second quarter of 2016 as compared to $81 million in the second quarter of 2015, primarily due to the development programs related to the Company's dermatology product portfolio, as well as spending on brodalumab and programs acquired in the Salix acquisition.
    Net Income (Loss)
    Net loss in the second quarter of 2016 was $302 million as compared to a net loss of $53 million in the second quarter of 2015. Adjusted net income (non-GAAP) in the second quarter of 2016 was $488 million as compared to $751 million in the second quarter of 2015.
    Cash Flow
    Cash flow from operations was $448 million in the second quarter of 2016 as compared to $411 million in the second quarter of 2015, an increase of 9% over the same period in 2015.

    www.twst.com/update/valeant-pharmaceu...
  2. [verwijderd] 9 augustus 2016 17:54
    www.biopharmadive.com/news/is-the-new...

    Analysts weren't necessarily buying into what Valeant is selling. The Q&A portion of the call lasted an extra 40 minutes as analysts looked for clarification on plans. Wells Fargo's David Maris even went as far as to ask, "Are things really changing or is this just new paint on the same old shed?"

    Papa's response: " I'm absolutely confident we are making changes at Valeant today." Time will tell.
  3. forum rang 6 Chiddix 9 augustus 2016 19:18
    In het terugbrengen van de schuld d.m.v afstoten bepaalde activiteiten , heeft Valeant ook hun oog laten vallen op de deal met de Pharming Group. Of dit goed of slecht is voor de Pharming Group, is koffiedik kijken.
    Men heeft de konijnenfirma eruit gewipt. Potentiele overnemers van Pharming kunnen nu berekeningen maken wat zij op tafel moeten leggen.
    Vooralsnog mikt Pharming op wat altijd succesvol is verlopen, contact zoeken met zogenaamde investeerders. In ruil voor aandelen en warrants. Ditmaal naast uitgifte van schuldpapier bv een obligatie. Of dat lukt is een tweede. Een claim-emissie is onwaarschijnlijk.
  4. [verwijderd] 9 augustus 2016 20:50
    Valeant Pharmaceuticals International Inc has fielded unsolicited interest in its core assets from potential buyers and although the company is not actively shopping them, it will consider all offers, Chief Executive Joe Papa said on Tuesday.

    www.businessinsider.com/r-valeant-ceo...

    Valeant wordt overgenomen...

    Net op tijd weg daar!

    ;-)
  7. [verwijderd] 11 augustus 2016 08:11
    UPDATE: Valeant Pharma (VRX) Under Criminal Investigation - WSJ
    (Updated - August 10, 2016 6:47 PM EDT)

    Valeant Pharma (NYSE: VRX) shares are dropping after-hours Wednesday following reports from Wall Street Journal the company is under criminal investigation. Federal prosecutors are investigating if the company defrauded insurance companies by hiding its ties to mail-order pharmacy Philidor Rx Services LLC.
    The investigation could lead to criminal charges against former Philidor executives and Valeant, the report stated.
    "Valeant has been cooperating and continues to cooperate with the ongoing Southern District of New York investigation," a Valeant spokesperson told the Journal.
    VRX shares last traded down 3.7% to $26.30.
    Wed, 10 Aug 2016 18:47:00 -0400
    published by StreetInsider.com
  8. [verwijderd] 11 augustus 2016 08:19
    NABEURS -13% UPDATE 1-Valeant under criminal investigation -WSJ (Adds share fall, details on probe and company)

    Aug 10 (Reuters) - U.S. federal prosecutors are investigating whether drugmaker Valeant Pharmaceuticals International Inc defrauded insurers by hiding a relationship with pharmacy Philidor that boosted sales of its drugs, the Wall Street Journal reported, citing people familiar with the matter.

    Valeant's U.S. listed shares were down 12.2 percent at $24 in extended trading on Wednesday.

    Neither Valeant nor the U.S. attorney's office in Manhattan were immediately available for comment.

    Lawyers in the U.S. attorney's office in Manhattan are pursuing a theory that Valeant and Philidor Rx Services LLC allegedly defrauded insurers by concealing their ties, the WSJ said.

    It is expected to be the most serious investigation that Valeant currently faces, and could lead to criminal charges against former Philidor executives and Valeant as a company, the Journal added, citing one person. (http://on.wsj.com/2aMvQwS)

    Valeant cut ties with Philidor Rx Services last October after it was revealed that the specialty pharmacy used aggressive tactics to try to increase insurer reimbursement, mostly for dermatology drugs to help the Canadian drugmaker inflate revenue. [nL3N12T5VA] [nL1N12Q0SE]

    The probe revolves around whether the now-defunct Philidor made false statements to insurers about its ties to Valeant, and whether insurers thought Philidor was neutral rather than in the service of Valeant, the Journal reported.

    The government lawyers are also looking at certain Philidor business practices, such as rebates and other compensation provided by the pharmacy to customers who used Valeant products, as well as Philidor's efforts to seek reimbursement from insurers, the WSJ said.

    Political concerns about Valeant's drug price increases and investor scrutiny of its dealings with Philidor dragged down Valeant's shares last fall.


    (Reporting by Anya George Tharakan in Bengaluru; Editing by Jonathan Oatis and Matthew Lewis)
  9. [verwijderd] 11 augustus 2016 13:02
    Valeant Pharma (VRX) Issues Statement on SDNY Investigation; Will Not Comment on Rumors

    Valeant Pharmaceuticals International, Inc. (NYSE: VRX) issued the following statement regarding the ongoing investigation being conducted by the U.S. Attorney's Office for the Southern District of New York:

    "Valeant previously disclosed in October 2015 that the United States Attorney's Office for the Southern District of New York commenced an investigation involving Valeant. We have been fully cooperating with the authorities throughout the investigation, and we are in frequent contact and continue to cooperate with the U.S. Attorney's Office for the Southern District of New York. We do not comment on rumors about investigations, and cannot comment on or speculate about the possible course of any ongoing investigation.

    "Valeant takes these matters seriously and intends to uphold the highest standards of ethical conduct as we move forward with our mission to improve people's lives with our healthcare products."
  11. [verwijderd] 11 augustus 2016 14:55
    Valeant lichtte mogelijk verzekeraars op
    Gepubliceerd op 11 aug 2016 om 14:10 |
    Pharming (14:36)
    EUR 0,251 +0,034 (+15,67%)

    Valeant Pharmaceuticals heeft mogelijk verzekeraars opgelicht door de connectie te verhullen met een postorderapotheek die de medicijnen van Valeant verkoos boven goedkopere alternatieven. Dit meldden bronnen aan The Wall Street Journal.

    Postorderapotheek Philidor, die niet langer bestaat, heeft mogelijk valse verklaringen afgelegd aan verzekeraars over de banden met Valeant. Philidor zou patiënten hebben bediend met de vergoeding van duurdere Valeant medicijnen, in plaats van goedkopere alternatieven, waardoor de objectiviteit van de postorderapotheek in twijfel wordt getrokken, zei een bron tegen de Amerikaanse zakenkrant.

    Een woordvoerster van Valeant zei in een reactie dat het bedrijf meewerkt aan alle onderzoeken van de Amerikaanse Justitie, die geen reactie wilde geven. Philidor zei eerder al dat zijn werknemers ethisch hebben gehandeld.

    Het onderzoek, dat mogelijk nog dit jaar wordt afgerond, kan leiden tot strafrechtelijke vervolging tegen voormalige managers van Philidor en Valeant als bedrijf, zei één van de bronnen.

    Valeant wordt achtervolgd door problemen. Er liepen al onderzoeken naar de distributie en prijsstelling van geneesmiddelen van het bedrijf. Daarnaast werd topman Michael Pearson eerder dit jaar vervangen door Joseph Papa.

    Hij kondigde eerder deze week bij de kwartaalcijfers aan schoon schip te willen maken door "een nieuwe strategische richting" in te gaan, waarbij het bedrijf een reorganisatie zal doorvoeren. Details werden verder niet verstrekt.

    Wel werd bekend dat Valeant de Noord-Amerikaanse rechten op Ruconest, een middel tegen angio-oedeem, gaat terug verkopen aan het Nederlandse Pharming.

    In het kwartaal dat eind juni eindigde, werd onder aan de streep een verlies geboekt van circa 302 miljoen dollar tegenover een verlies van 15 miljoen dollar een jaar eerder.

    De aangepaste winst per aandeel daalde van 2,14 naar 1,40 dollar terwijl de omzet op jaarbasis met 11 procent afnam tot 2,4 miljard dollar.

    Tsja... wat ik al eerder gemeld heb hier... net op tijd weg daar...Anders is je naam zo besmet.
  15. Rob 74 11 augustus 2016 16:58
    quote:

    Herman de Stier schreef op 11 augustus 2016 15:17:

    Die Sijmen, die heeft een goed gevoel voor timing.

    Groet,

    Herman
    Dat zal de toekomst uitwijzen, persoonlijk denk ik dat het zeer goed is zelf de verkoop voor 100% te hebben. Dan ben je er zelf verantwoordelijk voor en kun je sturen.
  17. [verwijderd] 11 augustus 2016 17:16
    A New Valeant Starts To Take Shape, And It's Still Not Pretty

    New threat

    However, Valeant has not recovered yet – far from it. Yesterday Mr Papa cautioned that, while the company remained within maintenance covenants covering its bank debt, “our cushion is not as large as I would like it to be”. Covenant breach would be a serious problem, allowing holders of Valeant debt to demand their money back immediately.

    That debt in total stands at over $31bn, including several tranches of term loans and senior notes, the really onerous part of which starts falling due in 2018. It is the reason why less than a third of Valeant’s $41bn enterprise value is reflected in its equity.

    full article:
    seekingalpha.com/article/3998738-new-...
353 Posts
Pagina: «« 1 ... 11 12 13 14 15 ... 18 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Markt lijkt groeipotentieel Pharming te onderschatten

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. 10 mei RBC verlaagt koersdoel Pharming
  2. 08 mei Update: Flinke omzetstijging Pharming 2
  3. 08 mei AEX houdt 900 punten waarschijnlijk niet vast, zorgen Ahold, Pharming en SBM voor spektakel? 2
  4. 19 apr Pharming lost voor 123 miljoen euro aan obligaties af
  5. 18 apr Pharming rondt plaatsing obligaties af 5
  6. 18 apr Pharming vervangt converteerbare lening 6
  7. 08 apr Pharming rondt rekrutering voor klinische studie leniolisib met kinderen af
  8. 14 mrt CEO: Pharming haalt omzet uit steeds meer landen 2
  9. 14 mrt Lichte plus voor AEX voorzien; zullen Pharming en Basic-Fit de boel opschudden?
  10. 14 mrt Pharming rekent ook voor 2024 op dubbelcijferige omzetgroei 2

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!